ABSTRACT
Breast cancer resistance protein (BCRP) belongs to the family of ATP-binding cassette (ABC) transporters, overexpression of which can confer a multidrug-resistant phenotype in cancer cells and tumors. BCRP mediates efflux of numerous xenobiotics, including various chemotherapeutic agents and photosensitizers. Hypericin (HY) is a naturally-occurring photosensitizer synthesized by plants of the genus Hypericum. Our recently published results indicate that accumulation of HY in cancer cells of different tissue origin can be affected mostly by BCRP. Considering all known facts, the main goal of this study was to verify whether not only HY accumulation but also toxicity of HY-mediated photodynamic therapy (PDT) can be affected by the presence of some ABC transporters. To specifically prove our hypothesis, we used an experimental model of human leukemia cell lines differing in the expression level of the main drug efflux transporters P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and BCRP. The lowest HY accumulation, and consequently the highest resistance to HY-PDT, was found in cells overexpressing BCRP. Moreover, pretreatment with BCRP inhibitor Ko143 significantly increased HY accumulation and sensitized cells to HY-PDT. Therefore, our findings represent direct evidence that BCRP is the nemesis of HY accumulation and toxicity of HY-PDT. Thus, we should emphasize that individualized screening for BCRP expression and activity may represent a useful tool for prediction of HY-mediated photodynamic diagnosis (PDD) or PDT effectiveness.
Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Breast Neoplasms/metabolism , Drug Resistance, Neoplasm/drug effects , Neoplasm Proteins/metabolism , Perylene/analogs & derivatives , Photochemotherapy , Radiation-Sensitizing Agents/metabolism , Anthracenes , Antineoplastic Agents/metabolism , Antineoplastic Agents/toxicity , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm/physiology , Female , HL-60 Cells , Humans , Perylene/antagonists & inhibitors , Perylene/metabolism , Perylene/toxicity , Photochemotherapy/adverse effects , Radiation-Sensitizing Agents/toxicityABSTRACT
The effect of hypericin photoactivation on mitochondria of human prostate carcinoma cells was studied using a range of mitochondrial inhibitors. Oligomycin significantly enhanced hypericin phototoxicity while atractyloside and antymicin A conferred a significant protection. Use of myxothiazol did not affect cell survival following hypericin photoactivation. These results signify a protective role for F(1)F(0)-ATP synthase running in reverse mode, and a significant photodamage at the quinone-reducing site of mitochondrial complex III. In light of these results, we performed molecular modeling of hypericin binding to complex III. This revealed three binding sites, two of which coincided with the quinol-oxidizing and quinone-reducing centers. Using submitochondrial particles we examined hypericin as a possible substrate of complex III and compared this to its natural substrate, ubiquinone-10. Our results demonstrate uniquely that hypericin is an efficient substrate for complex III, and this activity is inhibited by myxothiazol and antimycin A. We further demonstrated that hypericin photosensitization completely inactivated complex III with ubiquinone as substrate. The ability to enhance HYP potency by inhibition of F(1)F(0)-ATP synthase or depress HYP efficacy by inhibition at the Qi site of complex III provides a potential to increase the therapeutic index of HYP and amplify its PDT action in tumor cells.
Subject(s)
Electron Transport Complex III/metabolism , Light/adverse effects , Perylene/analogs & derivatives , Submitochondrial Particles/metabolism , Anthracenes , Antimycin A/pharmacology , Binding Sites , Cell Line, Tumor , Cytochromes c/chemistry , Electron Transport Complex III/antagonists & inhibitors , Electron Transport Complex III/chemistry , Humans , Methacrylates/pharmacology , Mitochondria/metabolism , Mitochondrial Proton-Translocating ATPases/metabolism , Models, Molecular , Perylene/antagonists & inhibitors , Perylene/chemistry , Perylene/metabolism , Perylene/toxicity , Spectrophotometry, Ultraviolet , Thiazoles/pharmacology , Ubiquinone/pharmacologyABSTRACT
Photodynamic therapy (PDT) is a novel and promising cancer treatment which employs a combination of a photosensitizing chemical and visible light to induce apoptosis in cancer cells. Singlet oxygen has been recognized as the main origin of oxidative stress in PDT. However, the precise mechanism of PDT-induced apoptosis is not well characterized, especially the dualistic role of nitric oxide (NO). To dissect the apoptosis pathways triggered by PDT, the intracellular free radicals in MCF-7 cells were investigated by examining a novel photosensitizer 2-butylamino-2-demethoxyhypocrellin B (2-BA-2-DMHB)-mediated PDT. It was found that exposure of the cells to 2-BA-2-DMHB and irradiation resulted in a significant increase of intracellular ROS in minutes, and then followed by cytoplasmic free calcium enhancement, mitochondrial nitric oxide synthase (mtNOS) activation, cytochrome c release, and apoptotic death. Scavengers of singlet oxygen or NO could attenuate PDT-induced cell viability loss, nucleus morphology changes, cytochrome c release, mitochondria swelling, and apo-apoptosis gene p53 and p21 mRNA levels. The results suggested that both ROS and NO played important roles in the apoptosis-induced by PDT.
